TY - JOUR
T1 - Proton pump inhibitor
T2 - The dual role in gastric cancer
AU - Joo, Moon Kyung
AU - Park, Jong Jae
AU - Chun, Hoon Jai
N1 - Funding Information:
Supported by Basic Science
Publisher Copyright:
© 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Proton pump inhibitors (PPIs) are one of the most frequently used medications for upper gastrointestinal diseases. However, a number of physicians have raised concern about the serious side effects of long-term use of PPIs, including the development of gastric cancer. Recent epidemiological studies have reported a significant association between long-term PPI intake and the risk of gastric cancer, even after successful Helicobacter pylori eradication. However, the effects of PPIs on the development of pre-malignant conditions such as atrophic gastritis or intestinal metaplasia are not fully known, suggesting the need for comprehensive and confirmative studies are needed in the future. Meanwhile, several experimental studies have demonstrated the effects of PPIs in reducing chemoresistance in gastric cancer cells by modulating the acidic microenvironment, cancer stemness and signal transducer and activator of transcription 3 (STAT3) signaling pathway. The inhibitory effects of PPIs on STAT3 activity may overcome drug resistance and enhance the efficacy of conventional or targeted chemotherapeutic agents. Taken together, PPIs may "play dual role" in gastric carcinogenesis and treatment of gastric cancer.
AB - Proton pump inhibitors (PPIs) are one of the most frequently used medications for upper gastrointestinal diseases. However, a number of physicians have raised concern about the serious side effects of long-term use of PPIs, including the development of gastric cancer. Recent epidemiological studies have reported a significant association between long-term PPI intake and the risk of gastric cancer, even after successful Helicobacter pylori eradication. However, the effects of PPIs on the development of pre-malignant conditions such as atrophic gastritis or intestinal metaplasia are not fully known, suggesting the need for comprehensive and confirmative studies are needed in the future. Meanwhile, several experimental studies have demonstrated the effects of PPIs in reducing chemoresistance in gastric cancer cells by modulating the acidic microenvironment, cancer stemness and signal transducer and activator of transcription 3 (STAT3) signaling pathway. The inhibitory effects of PPIs on STAT3 activity may overcome drug resistance and enhance the efficacy of conventional or targeted chemotherapeutic agents. Taken together, PPIs may "play dual role" in gastric carcinogenesis and treatment of gastric cancer.
KW - Astric cancer
KW - Drug resistance
KW - Proton pump inhibitor
KW - Signal transducer and activator of transcription 3
UR - http://www.scopus.com/inward/record.url?scp=85065887173&partnerID=8YFLogxK
U2 - 10.3748/wjg.v25.i17.2058
DO - 10.3748/wjg.v25.i17.2058
M3 - Article
C2 - 31114133
AN - SCOPUS:85065887173
SN - 1007-9327
VL - 25
SP - 2058
EP - 2070
JO - World journal of gastroenterology
JF - World journal of gastroenterology
IS - 17
ER -
